Hongyun Zhao

16PUBLICATIONS
97CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 24, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

|Jul 13, 2026
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

|Jun 01, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

|Mar 24, 2026
The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Mar 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.

Jiawei Lv, Dan-Xue Zheng, Jin-Hui Liang

|Mar 04, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Huaqiang Zhou, Hongyun Zhao, Xue Hou

Pageof 3

Frequent Collaborators

7 joint publications

Li Zhang

5 joint publications

Yuxiang Ma

5 joint publications

Yan Huang

5 joint publications

Wenfeng Fang